Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates
August 16, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is...
Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
March 17, 2021 08:30 ET
|
Cocrystal Pharma, Inc.
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...